The low-throughput protein A adsorber: an immune modulatory device. Hypothesis for the mechanism of action in the treatment of rheumatoid arthritis

References

• Abel JJ, Rowntree LG, Turner BB. Plasma removal with return of corpuscles (plasmapheresis). The Journal of Pharmacology and experimental therapeutics Vol. V. No. 6, July 1914. Transfus Sci 1990;11: 166–77.
   Google Scholar
• Jaffe IA. Comparison of the effect of plasmapheresis and penicil-lamine on the level of circulating rheumatoid factor. Ann Rheum Dis 1963;22:71–6.
   PubMed Web of Science ®Google Scholar
• Wallace DJ. How Prosorba apheresis came to be used for rheuma-toid arthritis: a personal historical perspective. Ther Apher 2001;5:76–8.
   PubMedGoogle Scholar
• Krakauer RS, Wysenbeek AJ, Wallace DJ, Jones JV, Smith JW, Malchesky P, et al. Therapeutic trial of cryofiltration in patients with rheumatoid arthritis. Am J Med 1983;74:951–5.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Barnett EV, Nichols S, Hancock W, Vibert G, Curd J, et al. Immunologic dynamics in cryapheresis for rheumatoid arthri-tis. J Ftheumatol 1983;10:894–900.
   Google Scholar
• Yamazaki Z, Idezuki Y, Inoue N, Yoshizawa H, Yamawaki N, Inagaki K, et al. Extracorporeal immunoadsorption with IM-PH or IM-TR column. Biomater Artif Cells Artif Organs 1989;17:117–24.
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Tsuda H, Kanai Y, Kobayashi S, Hirose S, Shinoura H, et al. Selective removal of anti-DNA and anticardiolipin anti-bodies by adsorbent plasmapheresis using dextran sulfate columns in patients with systemic lupus erythematosus. J Ftheumatol 1991;18:545–51.
   Google Scholar
• Sueoka A. Present status of apheresis technologies, part 3: adsor-bent. Ther Apher 1997;1:271–83.
   PubMedGoogle Scholar
• Yoshida M, Tamura Y, Yamada Y, Yamawaki N, Yamashita Y. Immusorba TR and Immusorba PH: basics of design and features of functions. Ther Apher 1998;2:185–92.
   Google Scholar
• Braun N, Ftisler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther Apher 1999;3:240–5.
   PubMedGoogle Scholar
• Wallukat G, Muller J, Hetzer R. Specific removal of betal -adren-ergic autoantibodies from patients with idiopathic dilated cardi-omyopathy. N Engl J Med 2002;347:1806.
   Google Scholar
• Bladon J, Taylor P. Extracorporeal photopheresis reduces the number of mononuclear cells that produce pro-inflammatory cytokines, when tested ex-vivo. J Clin Apheresis 2002;17:177–82.
   PubMed Web of Science ®Google Scholar
• Wiesenhutter CW, Irish BL, Bertram JH. Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: a pilot trial. J Ftheumatol 1994;21: 804–12.
   Google Scholar
• Jensen K. Acta Allerg 1959;13: 89–100.
   Google Scholar
• Lofdahl S, Guss B, Uhlen M, Philipson L, Lindberg M. Gene for staphylococcal protein A. Proc Natl Acad Sci USA 1983;80:697–701.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Guss B, Nilsson B, Gatenbeck S, Philipson L, Lindberg M. Complete sequence of the staphylococcal gene encoding pro-tein A. A gene evolved through multiple duplications. J Biol Chem 1984;259:1695–702.
   PubMed Web of Science ®Google Scholar
• Alonso DO, Daggett V. Staphylococcal protein A: unfolding path-ways, unfolded states, and differences between the B and E do-mains. Proc Natl Acad Sci USA 2000;97:133–8.
   PubMed Web of Science ®Google Scholar
• Matic G, Bosch T, Ramlow W. Background and indications for protein A-based extracorporeal immunoadsorption. Ther Apher 2001;5:394–403.
   Google Scholar
• Sasso EH, Merrill C, Furst TE. Immunoglobulin binding proper-ties of the Prosorba immunoadsorption column in treatment of rheumatoid arthritis. Ther Apher 2001;5:84–91.
   Google Scholar
• Radaev S, Sun P. Recognition of immunoglobulins by Fcgamma receptors. Mol Immunol 2002;38:1073–83.
   PubMed Web of Science ®Google Scholar
• Graille M, Stura EA, Corper AL, Sutton BJ, Taussig MJ, Charbonnier JB, et al. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgIVI antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci USA 2000;97:5399–404.
   PubMed Web of Science ®Google Scholar
• Matic G, Hofmann D, Winkler R, Tiess M, Michelsen A, Schneidewind JM, et al. Removal of immunoglobulins by a protein A versus an antihuman immunoglobulin G-based system: evalua-tion of 602 sessions of extracorporeal immunoadsorption. Artif Organs 2000;24:103–7.
   PubMed Web of Science ®Google Scholar
• Deisenhofer J. Crystallographic refinement and atomic models of a human Fe fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochem-istry 1981;20:2361–70.
   PubMed Web of Science ®Google Scholar
• Silverman GJ, Cary SP, Dwyer DC, Luo L, Wagenknecht R, Curtiss VE. A B cell superantigen-induced persistent "Hole" in the B-1 repertoire. J Exp Med 2000;192:87–98.
   PubMed Web of Science ®Google Scholar
• Kozlowski LM, Li W, Goldschmidt M, Levinson Al. In vivo inflammatory response to a prototypic B cell superantigen: elicita-tion of an Arthus reaction by staphylococcal protein A. J Immunol 1998;160:5246–52.
   PubMed Web of Science ®Google Scholar
• Cary S, Krishnan M, Marion TN, Silverman GJ. The murine clan V(H) III related 7183, J606 and S107 and DNA4 families com-monly encode for binding to a bacterial B cell superantigen. Mol Immunol 1999;36:769–76.
   PubMed Web of Science ®Google Scholar
• Goodyear CS, Silverman GJ. Death by a B Cell Superantigen: In vivo VH-targeted apoptotic supraclonal B cell deletion by a sta-phylococcal toxin. J Exp Med 2003;197:1125–39.
   PubMed Web of Science ®Google Scholar
• Silverman GJ, Pires R, Bouvet JP. An endogenous sialoprotein and a bacterial B cell superantigen compete in their VH family-specific binding interactions with human Igs. J Immunol 1996;157: 4496–502.
   Google Scholar
• Silverman GJ. Adoptive transfer of a superantigen-induced hole in the repertoire of natural IgM-secreting cells. Cell Immunol 2001;209:76–80.
   PubMed Web of Science ®Google Scholar
• Sinha P, Ghosh AK, Das T, Sa G, Ray PK. Protein A of Staphylo-coccus aureus evokes Thl type response in mice. Immunol Lett 1999;67:157–65.
   Google Scholar
• Hartleib J, Kohler N, Dickinson RB, Chhatwal GS, Shona JJ, Hartford OM, et al. Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. Blood 2000;96:2149–56.
   PubMed Web of Science ®Google Scholar
• Steele G Jr, Ankerst J, Sjogren HO. Alteration of in vitro anti-tumor activity of tumor-bearer sera by absorption with Staphylo-coccus aureus, Cowan I. Int J Cancer 1974;14:83–92.
   Google Scholar
• Gendreau RM. A randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis. Ther Apher 2001;5:79–83.
   PubMedGoogle Scholar
• Kunkel S, Holtz M, Grossjohann B, Schuett W, Klinkmann H, Kong D, et al. Selective removal of circulating immune complexes from patient plasma. Artif Organs 2002;26:124–32.
   PubMed Web of Science ®Google Scholar
• Felson DT, LaValley MP, Baldassare AR, Block JA, Caldwell JR, Cannon GW, et al. The Prosorba column for treatment of refrac-tory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. Arthritis Rheum 1999;42:2153–9.
   PubMed Web of Science ®Google Scholar
• Nakaji S. Current topics on immunoadsorption therapy. Ther Apher 2001;5:301–5.
   PubMedGoogle Scholar
• Javeed M, Nifong TP, Domen RE, Rybka WB. Durable response to combination therapy including staphylococcal protein A immunoadsorption in life-threatening refractory autoimmune hemolysis. Transfusion 2002;42:1217–20.
   PubMed Web of Science ®Google Scholar
• Caldwell J, Gendreau RM, Furst D, Wiesenhutter C, Quagliata F, Spindler J, et al. A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritis. J Ftheumatol 1999;26:1657–62.
   Google Scholar
• Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991;67:869–77.
   PubMed Web of Science ®Google Scholar
• Nakaji S, Hayashi N. Bilirubin adsorption column Medisorba BL-300. Ther Apher Dial 2003;7:98–103.
   PubMed Web of Science ®Google Scholar
• Fennelly DW, Norton L, Sznol M, Hakes TB. A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with Prosorba columns for treating metastatic breast cancer. Cancer 1995;75:2099–102.
   PubMed Web of Science ®Google Scholar
• Snyder HW Jr, Henry DH, Messerschmidt GL, Mittelman A, Bertram J, Ambinder E, et al. Minimal toxicity during protein A immunoadsorption treatment of malignant disease: an outpatient therapy. J Clin Apheresis 1991;6:1–10.
   PubMedGoogle Scholar
• Braun N, Erley C, Klein R, Kotter I, Saal J, Ftisler T. Immunoa-dsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant 2000;15:1367–72.
   PubMed Web of Science ®Google Scholar
• Furst D, Felson D, Thoren G, Gendreau RM. Immunoadsorption for the treatment of rheumatoid arthritis: final results of a rando-mized trial. Prosorba Trial Investigators. Ther Apher 2000;4:363–73.
   PubMedGoogle Scholar
• Snyder HW Jr, Cochran SK, Bailin JP Jr, Bertram JH, Mittelman A, Guthrie TH Jr, et al. Experience with protein A-immunoa-dsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood 1992;79:2237–45.
   Google Scholar
• Snyder HW Jr, Mittelman A, Oral A, Messerschmidt GL, Henry DH, Korec S, et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syn-drome by protein A immunoadsorption of plasma. Cancer 1993;71: 1882–92.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Allen E, Daoud K, Wahba I. Vasculitis secondary to staphylococcal Protein A immunoadsorption (Prosorba column) treatment in rheumatoid arthritis. Semin Arthritis Rheum 2002; 32:3–9.
   PubMed Web of Science ®Google Scholar
• Ainsworth SK, Pilia PA, Pepkowitz SH, O'Brien P. Toxicity fol-lowing protein A treatment of metastatic breast adenocarcinoma. Cancer 1988;61:1495–500.
   Google Scholar
• Shumak KH, Rock GA. Therapeutic plasma exchange. N Engl J Med 1984;310:762–71.
   PubMed Web of Science ®Google Scholar
• Jefferis R, Mageed RA. The specificity and reactivity of rheuma-toid factors with human IgG. Monogr Allergy 1989;26:45–60.
   PubMedGoogle Scholar
• Mannik M, Nardella FA. IgG rheumatoid factors and self-association of these antibodies. Clin Rheum Dis 1985;11:551–72.
   PubMedGoogle Scholar
• Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999;97:188–96.
   Google Scholar
• Levo Y, Fischel R, Ehrenfeld M. Circulating immune complexes in patients with rheumatoid arthritis: correlation with disease activity. J Ftheumatol 1981;8:851–5.
   Google Scholar
• Sutton B, Corper A, Bonagura V, Taussig M. The structure and origin of rheumatoid factors. Immunol Today 2000;21:177–83.
   PubMedGoogle Scholar
• Sato HY, Yamagata Y, Kidaka T. Studies on quantitative levels of complement activation induced by immobilized and soluble forms of protein A: relevance to extracorporeal immunoadsorption. Transfus Sci 1991;12:299–305.
   Google Scholar
• Balint JP Jr, Jones FR. Evidence for proteolytic cleavage of co-valently bound protein A from a silica based extracorporeal immunoadsorbent and lack of relationship to treatment effects. Transfus Sci 1995;16:85–94.
   PubMedGoogle Scholar
• Silverman GJ, Goodyear CS. A model B-cell superantigen and the immunobiology of B lymphocytes. Clin Immunol 2002;102:117–34.
   PubMed Web of Science ®Google Scholar
• Unkeless JC, Scigliano E, Freedman VH. Structure and function of human and murine receptors for IgG. Annu Rev Immunol 1988; 6:251–81.
   PubMed Web of Science ®Google Scholar
• Fridman WH. Fe receptors and immunoglobulin binding factors. FASEB J 1991;5:2684–90.
   PubMed Web of Science ®Google Scholar
• Ravetch JV, Kinet JP. Fe receptors. Annu Rev Immunol 1991;9: 457–92.
   PubMed Web of Science ®Google Scholar
• Hulett MD, Hogarth PM. Molecular basis of Fe receptor function. Adv Immunol 1994;57:1–127.
   PubMed Web of Science ®Google Scholar
• Daeron M. Fe receptor biology. Annu Rev Immunol 1997;15:203–34.
   PubMed Web of Science ®Google Scholar
• Tamm A, Kister A, Nolte KU, Gessner JE, Schmidt RE. The IgG binding site of human FcgammaFtIIIB receptor involves CC' and FG loops of the membrane-proximal domain. J Biol Chem 1996; 271:3659–66.
   Google Scholar
• Ravetch JV, Bolland S. IgG Fe receptors. Annu Rev Immunol 2001;19:275–90.
   PubMed Web of Science ®Google Scholar
• Galon J, Gauchat JF, Mazieres N, Spagnoli R, Storkus W, Lotze M, et al. Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement recep-tors. J Immunol 1996;157:1184–92.
   PubMed Web of Science ®Google Scholar
• Vaughan JH. 1992 Joseph J. Bunim Lecture. Pathogenetic con-cepts and origins of rheumatoid factor in rheumatoid arthritis. Arthritis Rheum 1993;36:1–6.
   Google Scholar
• Sato Y, Watanabe H, Kogure A, Miyata M, Watanabe K, Nishimaki T, et al. Complement-activating properties of IgIVI rheu-matoid factors reacting with IgG subclasses. Clin Ftheumatol 1995;14:425–8.
   PubMed Web of Science ®Google Scholar
• Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, t Hart BA, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998;41:1481–8.
   PubMed Web of Science ®Google Scholar
• Lu EW, Deftos M, Tighe H, Carson DA, Chen PP. Generation and characterization of two monoclonal self-associating IgG rheuma-toid factors from a rheumatoid synovium. Arthritis Rheum 1992; 35:101–5.
   Google Scholar
• Arason GJ, D'Ambrogio MS, Vikingsdottir T, Sigfusson A, 75. Valdimarsson H. Enzyme immunoassays for measuring comple-ment-dependent prevention of immune precipitation (PIP) and solubilization of preformed antigen- antibody complexes (SQL). J 76. Immunol Methods 1999;223: 37–46.
   Google Scholar
• Schifferli JA, Bartolotti SR, Peters DK. Inhibition of immune pre-cipitation by complement. Clin Exp Immunol 1980;42:387–94.
   PubMed Web of Science ®Google Scholar
• Naama JK, Hamilton AO, Yeung-Laiwah AC, Whaley K. Preven- 77. tion of immune precipitation by purified classical pathway comple-ment components. Clin Exp Immunol 1984;58: 486–92.
   Google Scholar
• Miller GW, Nussenzweig V. A new complement function: solubili-zation of antigen-antibody aggregates. Proc Natl Acad Sci USA 78. 1975;72:418–22.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Takahashi S, Brade V, Nussenzweig V. Require-ments for the solubilization of immune aggregates by complement. The role of the classical pathway. J Clin Invest 1978;62:349–58.
   PubMed Web of Science ®Google Scholar
• Spath PJ, Pascual M, Meyer-Hanni L, Schaad UB, Schifferli JA. Solubilization of immune precipitates by complement in the ab-sence of properdin or factor D. FEBS Lett 1988;234:131–4.
   Google Scholar
• Schifferli JA, Steiger G, Paccaud JP. Complement mediated inhibi-tion of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a). Clin Exp Immunol 1986;64: 407–14.
   Google Scholar
• Snyder HW Jr, Balint JP Jr, Jones FR. Modulation of immunity in patients with autoimmune disease and cancer treated by extracor-poreal immunoadsorption with Prosorba columns. Semin Hematol 1989;26:31–41.
   PubMed Web of Science ®Google Scholar
• Griffiths RI, Slurzberg JE. Cost-effectiveness of Prosorba column therapy for rheumatoid arthritis: a framework for analysis. Ther Apher 2001;5:105–10.
   PubMedGoogle Scholar